AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

Discover how to navigate inflation with long-term investments in resilient companies like Coca-Cola, AbbVie, and TC Energy.

AbbVie closed out the year on a high note, as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s ...

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...

Skyrizi had an estimated national TV ad spend of $367.7 million — the highest ad spend of any brand in the top 10.

Guggenheim Securities adjusted its financial outlook for shares of AbbVie Inc . (NYSE:ABBV), reducing the price target to $212 from the previous $221, while still recommending a Buy rating for the ...

Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

These characteristics make dividend growth stocks compelling investments in any market environment. The strategy's success ...

Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...